9M 2023 Financial Performance

9M 2023: Business update Continued strong momentum for Vyepti 5 U.S. Vyepti revenue (DKKm) RoW Vyepti revenue (DKKm) DKK 657m +73% CER DKK 1,119m DKK 15m +447% CER vyepti TM Vyepti's 9M 2023 global revenue up 81% • Lundbeck's full investment behind the brand continues to drive growth DKK 82m • Continued strong performance driven by new patients starts 9M 2022 9M 2023 United States 9M 2022 Europe 9M 2023 International Markets Vyepti was approved by FDA in February 2020 and by the EU Commission in January 2022. 1) Wholesalers dispensing data (weekly numbers of vials), latest datapoint ending October 6, 2023. Unless otherwise stated, growth rates are at CER Global rollout on track Launched in ten markets in 2023 Secured coverage for 80% of Canadians across healthcare plans Vyepti approved as first reimbursed migraine IV treatment in Australia

View entire presentation